Also known as: Lonza
Flow chemistry, laboratory mixer, and industrial extruder markets are projected to grow significantly through 2035, driven by pharmaceutical continuous manufacturing, high R&D funding, and sustainability trends. Flow chemistry is expected to reach $12 billion, while laboratory mixers could hit $29.6 billion. Key players include Merck KGaA, BASF, and Lonza.
Lonza announced a licensing agreement with Engitix to develop ADCs using its technology platform, alongside an expansion of its Advanced Synthesis offering that integrates GlycoConnect, HydraSpace, and toxSYN technologies. The Oss site has been upgraded to support bioconjugate R&D and pilot toxicology supply.
Cell culture media bags, medical-grade PCR packaging, cold chain packaging, and Ireland sterile injectables CDMO markets are forecast to grow through 2035-2036, with CAGRs ranging from 9.2% to 11.8%.
Drug discovery success hinges on target, modality, and indication; over two-thirds of programs fail in Phase 2. Integrated strategies and disease-relevant models help reduce attrition. A Lonza webinar on April 22, 2026 covers CRISPR screening.
The mRNA synthesis and manufacturing market is projected to grow from USD 2.23 billion in 2024 to USD 2.96 billion by 2029 at a 5.8% CAGR. Consumables led in 2023, while Asia Pacific is expected to be the fastest-growing region.
LigaChem Biosciences is expanding R&D investment in its ADC pipeline despite widening losses, with major clinical milestones expected this year. Concurrently, Lonza has enhanced its advanced synthesis capabilities for ADC development, including dual-payload technology and expanded Netherlands facility infrastructure.
